Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Stock Price Down 9.3%

Calliditas Therapeutics AB (publ) (NASDAQ:CALT)’s stock price was down 9.3% during mid-day trading on Monday . The company traded as low as $17.68 and last traded at $17.68. Approximately 1,992 shares traded hands during mid-day trading, a decline of 74% from the average daily volume of 7,694 shares. The stock had previously closed at $19.50.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $50.00 price target on shares of Calliditas Therapeutics AB (publ) in a report on Thursday, February 22nd.

Calliditas Therapeutics AB (publ) Price Performance

The stock’s 50-day moving average price is $20.77 and its 200 day moving average price is $20.67. The company has a current ratio of 3.13, a quick ratio of 3.08 and a debt-to-equity ratio of 2.89.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) last announced its quarterly earnings data on Wednesday, February 21st. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.02. The business had revenue of $42.45 million during the quarter, compared to analyst estimates of $36.24 million. Calliditas Therapeutics AB (publ) had a negative net margin of 38.72% and a negative return on equity of 104.47%. During the same quarter in the prior year, the business earned ($0.01) earnings per share. Equities analysts predict that Calliditas Therapeutics AB will post 0.29 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Calliditas Therapeutics AB (publ) stock. Optiver Holding B.V. purchased a new position in Calliditas Therapeutics AB (publ) (NASDAQ:CALT) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 980 shares of the company’s stock, valued at approximately $25,000. Hedge funds and other institutional investors own 2.83% of the company’s stock.

About Calliditas Therapeutics AB (publ)

Calliditas Therapeutics AB (publ), a commercial-stage specialty pharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.